Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Sep
25
Today In Oncology
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
Robert Kyle Myeloma Expert Dies at 98
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo